GenBioPro, Inc. (“GBP”) is a private, specialty pharmaceutical company that is engaged in the regulatory approval and commercialization of "super-generic" drugs and "biosimilar" biotechnology products. The Company has leveraged relationships with pharmaceutical, drug delivery, and biotechnology product manufacturers around the world to provide lower cost, high quality life-saving medical products that can be sold by the Company at tremendously reduced costs, thus lowering the price of life-saving medicines to people in the U.S. and abroad.

GBP's primary mission is to gain regulatory market approvals in North America, Latin America, Europe, and all other global markets for a significant pipeline of low cost, high quality, life-saving medical products. We are "driven to improve human life" around the world.     Learn more »

GenBioPro is partnering with drug delivery companies to develop patented extended-release and "needle-free" delivery methods, including oral, buccal, transdermal, and inhalation, for its generic drugs and biosimilar biotechnology products; "needle-free" delivery will eliminate the need for repeated, painful, daily needle injections resulting in better patient acceptance and compliance.
Learn more »

GenBioPro has a pipeline of life-saving medical products at various stages of commercial sales and development. Many products are already approved in markets outside the U.S. and will be approved in the U.S. within 1-2 years while other products are approved in the U.S. and will be sold in countries outside in U.S. in less than a year. GBP will provide life-saving products to developing countries to improve human life of people in the much-needed, under-served areas of the world, and GBP will "gift" 5% of the Company's annual profit to humanitarian efforts around the world.
Learn more »